

**Information regarding the total number of shares and voting rights
pursuant to article L.233-8 II of the Commercial code
and article 223-16 of the general regulation of the financial markets Authority**

Situation as at July 31st, 2024

| | |
|--|---------------------------|
| Total number of shares forming the share capital | 18,168,892 ⁽¹⁾ |
| Total number of theoretical voting rights | 18,168,892 |
| Total number of exercisable voting rights | 18,131,604 |

⁽¹⁾ *out of which 509,000 shares (exercise price between 3.00€ to 3.99€) issued pursuant to the "Equity Line" financing with Kepler Cheuvreux SA corresponding to 3.5% of traded volumes and raising a total amount of 1,806,700€ since its implementation on November 14th, 2022. A shareholder owning 1% of the capital of Global Bioenergies SA on November 13th, 2022 would have had its stake diluted to 0.970% of the capital on July 31st, 2024.*

Monthly summary of the number of shares issued pursuant to the “Equity Line” financing with Kepler Cheuvreux SA:

| <i>Month</i> | <i>Number of shares issued</i> |
|-----------------------|--------------------------------|
| <i>November 2022</i> | <i>48,000</i> |
| <i>December 2022</i> | <i>61,000</i> |
| <i>January 2023</i> | <i>50,000</i> |
| <i>February 2023</i> | <i>-</i> |
| <i>March 2023</i> | <i>-</i> |
| <i>April 2023</i> | <i>-</i> |
| <i>May 2023</i> | <i>-</i> |
| <i>June 2023</i> | <i>350,000</i> |
| <i>July 2023</i> | <i>-</i> |
| <i>August 2023</i> | <i>-</i> |
| <i>September 2023</i> | <i>30,000</i> |
| <i>October 2023</i> | <i>-</i> |
| <i>November 2023</i> | <i>-</i> |
| <i>December 2023</i> | <i>-</i> |
| <i>January 2024</i> | <i>-</i> |
| <i>February 2024</i> | <i>-</i> |
| <i>March 2024</i> | <i>-</i> |
| <i>April 2024</i> | <i>-</i> |
| <i>May 2024</i> | <i>-</i> |
| <i>June 2024</i> | <i>-</i> |
| <i>July 2024</i> | <i>-</i> |

Listing market: Euronext Growth Paris

Mnemo code: ALGBE

ISIN code: FR 0011052257